Details for Patent: 9,180,197
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which drugs does patent 9,180,197 protect, and when does it expire?
Patent 9,180,197 protects PERSERIS KIT and is included in one NDA.
This patent has eighteen patent family members in eleven countries.
Summary for Patent: 9,180,197
Title: | Sustained delivery formulations of risperidone compounds |
Abstract: | The present invention relates to a risperidone sustained release delivery system for treatment of medical conditions relating delusional psychosis, schizophrenia, bipolar disorder, psychotic depression, obsessive-compulsion disorder, Tourette syndrome, and autistic spectrum disorders. The sustained release delivery system includes a flowable composition containing risperidone, a metabolite, or a prodrug thereof and an implant containing risperidone, a metabolite, or a prodrug thereof. The flowable composition may be injected into tissue whereupon it coagulates to become the solid or gel, monolithic implant. The flowable composition includes a biodegradable, thermoplastic polymer, an organic liquid, and risperidone, a metabolite, or a prodrug thereof. |
Inventor(s): | Dadey; Eric (Furlong, PA) |
Assignee: | Indivior UK Limited (Slough, GB) |
Application Number: | 14/490,034 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,180,197 |
Patent Claim Types: see list of patent claims | Composition; Compound; Device; |
Drugs Protected by US Patent 9,180,197
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Indivior Inc | PERSERIS KIT | risperidone | FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS | 210655-001 | Jul 27, 2018 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | ||||
Indivior Inc | PERSERIS KIT | risperidone | FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS | 210655-002 | Jul 27, 2018 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,180,197
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Australia | 2008262545 | See Plans and Pricing | |||
Brazil | PI0811319 | See Plans and Pricing | |||
Canada | 2687979 | See Plans and Pricing | |||
China | 101801415 | See Plans and Pricing | |||
European Patent Office | 2152315 | See Plans and Pricing | |||
European Patent Office | 2907524 | See Plans and Pricing | |||
Spain | 2562878 | See Plans and Pricing | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |